Frederick S. Vizeacoumar

Citata da

	Tutte	Dal 2019
Citazioni	2813	1731
Indice H	23	22
i10-index	39	37

320

160

240

20102011201220132014201520162017201820192020202120222023202413 29 57 101 140 142 191 169 203 241 262 313 315 297 303

Accesso pubblico

Visualizza tutto

44 articoli

4 articoli

Disponibili

Non disponibili

In base ai mandati di finanziamento

Coautori

Franco VizeacoumarAssociate Professor, University of Saskatchewan, Saskatchewan Cancer AgencyEmail verificata su usask.ca
Andrew FreywaldProfessor University of SaskatchewanEmail verificata su usask.ca
Deborah AndersonDirector of Research, Saskatchewan Cancer AgencyEmail verificata su saskcancer.ca
Chelsea CunninghamSaskatchewan Health Research FoundationEmail verificata su mail.usask.ca
John YooProfessor Schulich School of Medicine & Dentistry Western UniversityEmail verificata su lhsc.on.ca
Paul C. BoutrosUniversity of California, Los AngelesEmail verificata su mednet.ucla.edu
Kara M. RuicciMD PhD, Radiation Oncology, University of TorontoEmail verificata su uwo.ca
Danielle MacneilWestern UniversityEmail verificata su lhsc.on.ca
Anthony C. Nichols, MD FRCSCProfessor, Department of Otolaryngology - Head and Neck Surgery, Western UniversityEmail verificata su lhsc.on.ca
john w. barrettlondon regional cancer programEmail verificata su lhsc.on.ca
Nicole PintoPhD, Western UniversityEmail verificata su uwo.ca
Zhaolei Zhang, ProfessorUniversity of Toronto, Donnelly Centre, Dept of Molecular Genetics, Dept of Computer ScienceEmail verificata su utoronto.ca
Benjamin J. BlencoweProfessor, University of TorontoEmail verificata su utoronto.ca
Hong HanAssistant Professor & Principal Investigator, McMaster UniversityEmail verificata su mcmaster.ca
Jeff WranaSenior Investigator, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto; Professor, Dept. of Mol. Gen., U. ofEmail verificata su lunenfeld.ca
Maruti UppalapatiUniversity of SaskatchewanEmail verificata su usask.ca
Joe MymrykProfessor of Microbiology & Immunology, Oncology and Otolaryngology, Western UniversityEmail verificata su uwo.ca
Jeff LiuUniversity Health NetworkEmail verificata su utoronto.ca
Eldad ZacksenhausProfessor of Medicine, University of TorontoEmail verificata su utoronto.ca
Sean EganCell Biology Program - The Hospital for Sick ChildrenEmail verificata su sickkids.ca

Segui

Frederick S. Vizeacoumar

Director, PICS Core facility, UofS

Email verificata su usask.ca

Bioinformatics Machine Learning Synthetic Lethality Synthetic Dosage Lethality


Titolo Ordina per citazioni Ordina per anno Ordina per titolo	Citata da Citata da	Anno
Systematic exploration of essential yeast gene function with temperature-sensitive mutants Z Li, FJ Vizeacoumar, S Bahr, J Li, J Warringer, FS Vizeacoumar, R Min, ... Nature biotechnology 29 (4), 361-367, 2011	453	2011
Essential gene profiles in breast, pancreatic, and ovarian cancer cells R Marcotte, KR Brown, F Suarez, A Sayad, K Karamboulas, ... Cancer discovery 2 (2), 172-189, 2012	383	2012
Global gene deletion analysis exploring yeast filamentous growth O Ryan, RS Shapiro, CF Kurat, D Mayhew, A Baryshnikova, B Chin, ... Science 337 (6100), 1353-1356, 2012	251	2012
Multilayered control of alternative splicing regulatory networks by transcription factors H Han, U Braunschweig, T Gonatopoulos-Pournatzis, RJ Weatheritt, ... Molecular cell 65 (3), 539-553. e7, 2017	177	2017
Integrating high-throughput genetic interaction mapping and high-content screening to explore yeast spindle morphogenesis FJ Vizeacoumar, N van Dyk, F S. Vizeacoumar, V Cheung, J Li, ... Journal of Cell Biology 188 (1), 69-81, 2010	117	2010
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities FJ Vizeacoumar, R Arnold, FS Vizeacoumar, M Chandrashekhar, ... Molecular systems biology 9 (1), 696, 2013	113	2013
Molecular characterization of breast cancer cell lines through multiple omic approaches SE Smith, P Mellor, AK Ward, S Kendall, M McDonald, FS Vizeacoumar, ... Breast Cancer Research 19, 1-12, 2017	104	2017
Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors SC Chafe, FS Vizeacoumar, G Venkateswaran, O Nemirovsky, S Awrey, ... Science advances 7 (35), eabj0364, 2021	98	2021
RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs TJW Robinson, JC Liu, F Vizeacoumar, T Sun, N Maclean, SE Egan, ... PloS one 8 (11), e78641, 2013	98	2013
Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming CL Hirsch, ZC Akdemir, L Wang, G Jayakumaran, D Trcka, A Weiss, ... Genes & development 29 (8), 803-816, 2015	89	2015
High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors T Robinson, M Pai, J Liu, F Vizeacoumar, T Sun, S Egan, A Datti, J Huang, ... Cell Cycle 12 (18), 3013-3024, 2013	86	2013
Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers AK Ward, P Mellor, SE Smith, S Kendall, NA Just, FS Vizeacoumar, ... Breast Cancer Research 18, 1-21, 2016	60	2016
Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2012; 2 (2): 172–89. doi: 10.1158/2159-8290 R Marcotte, KR Brown, F Suarez, A Sayad, K Karamboulas, ... CD-11-0224.[PubMed][Cross Ref], 2012	59	2012
Protein tyrosine kinases: their roles and their targeting in leukemia K K. Bhanumathy, A Balagopal, FS Vizeacoumar, FJ Vizeacoumar, ... Cancers 13 (2), 184, 2021	57	2021
PicOS: A Tiny Operating System for Extremely Small Embedded Platforms. E Akhmetshina, P Gburzynski, FS Vizeacoumar Embedded Systems and Applications, 116-122, 2003	49	2003
An integrated computational and experimental study uncovers FUT 9 as a metabolic driver of colorectal cancer N Auslander, CE Cunningham, BM Toosi, EJ McEwen, K Yizhak, ... Molecular Systems Biology 13 (12), 956, 2017	48	2017
EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours BM Toosi, A El Zawily, L Truitt, M Shannon, O Allonby, M Babu, ... Oncogene 37 (30), 4073-4093, 2018	42	2018
Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer F Ghasemi, M Black, F Vizeacoumar, N Pinto, KM Ruicci, CCSH Le, ... Oncotarget 8 (42), 71512, 2017	37	2017
A road map to personalizing targeted cancer therapies using synthetic lethality S Parameswaran, D Kundapur, FS Vizeacoumar, A Freywald, ... Trends in Cancer 5 (1), 11-29, 2019	35	2019
Discovering selective binders for photoswitchable proteins using phage display JM Reis, X Xu, S McDonald, RM Woloschuk, ASI Jaikaran, ... ACS synthetic biology 7 (10), 2355-2364, 2018	32	2018

Il sistema al momento non può eseguire l'operazione. Riprova più tardi.

Articoli 1–20

Citazioni per anno

Citazioni duplicate

Citazioni unite

Aggiungi coautoriCoautori

Segui

Citata da

Coautori